TY - JOUR AU - Arteaga, Carlos L. PY - 2003 DA - 2003/04/01 TI - Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer JO - Breast Cancer Research SP - 96 VL - 5 IS - 2 AB - Overexpression of the HER2/Neu (ErbB2) proto-oncogene is associated with breast cancer progression and poor patient prognosis. Herceptin (trastuzumab) is a humanized IgG1 against the ectodomain of the HER2 receptor. In combination with chemotherapy, it induces regression of HER2-overexpressing metastatic breast tumors and prolongs patient survival. Single-agent Herceptin in patients with HER2-amplified breast tumors also induces a definite objective response and clinical benefit rates, and is well tolerated. These data suggest that Herceptin is an effective first-line single-agent therapy for a predictable cohort of metastatic breast cancers and can therefore be used as a platform for therapeutic discovery against tumors that overexpress HER2. SN - 1465-542X UR - https://doi.org/10.1186/bcr574 DO - 10.1186/bcr574 ID - Arteaga2003 ER -